Starpharma Holdings Limited
Polyvalent dendrimer compounds
Starpharma Holdings Ltd is a publicly listed company specialising in the development and commercialisation of nanotechnology.  The company is currently capitalised at over $75 million.  Starpharma was established in 1996 as a public unlisted company. TSL's Managing Director, Ross Dobinson, was a founding director.

TSL was engaged by Starpharma to assist the Company in restructuring its business in a tax-effective way and to raise capital for its development.

TSL's Role:

• Advised on corporate structure and helped establish Starpharma as a Pooled Development Fund
• Raised over $13 million through two capital raisings
• Facilitated the listing of Starpharma on the Exempt Market through Austock Brokers Pty Ltd
• Assisted with a further capital raising of $22.4 million through an Initial Public Offer at $0.85 per share (following a 1:4 share split)
• Provided strategic business development advice, shareholder liaison and corporate advisory services
  

Starpharma is currently progressing licensing arrangements in the US through its wholly owned subsidiary - Dendritic Nanotechnologies Ltd (‘DNT’).

In October 2006 Starpharma acquired DNT expanding the company's potential products to include drug delivery and industrial specialty chemical appliances. Many of these applications have near-term cash flow opportunities.  In February 2007 Starpharma announced an exclusive license and supply agreement between DNT and EMD Biosciences (part of Merck KGaA) for the Priofect siRNA transfaction reagent.

To learn more about Starpharma Holdings Limited visit their web-site here.

Previous client | Next client